Mary Pitman
Mary Pitman, PhD, is a Staff Research Scientist at SandboxAQ, where she leads technological innovation in drug discovery and biologics. Dr. Pitman's groups develop new computational methods in antibody design, cell-scale AI models, and affinity prediction techniques for small molecules and biologics. Her background includes scientific software engineering for pharmaceutical and AI companies, academia, and the NIH. As a postdoctoral MolSSI software fellow, Dr. Pitman worked with David Mobley and discovered new AI and graph theoretic methods for drug discovery. During her doctorate, Dr. Pitman studied under Garegin Papoian as an Integrative Cancer Research fellow at the NCI/NIH. There, she derived new theoretical frameworks to model how epigenetics drive cancer.
SandboxAQ
Machine Learning and AI Tools to Guide Engineering of Human Therapeutics
-
Join us for an in-depth look at how biotechnology leaders are harnessing machine learning and data-driven approaches to engineer novel human therapeutics right now—well beyond the “someday” promises of AI. In this session, experts from pioneering organizations will share real-world insights into using big data and advanced analytics to accelerate everything from target discovery to clinical development. Discover how these teams are unlocking fresh possibilities for personalized treatments, improving success rates, and shaping the future of human health through powerful, actionable applications of ML and AI.
Conference Pass
2,495
USD
Keynotes & Firesides
Workshops & Breakouts
1:1 Partnering App
Meals & Receptions
Session Recordings
Until Friday April 18th
Full Rate:
$3,495